Filing Details

Accession Number:
0001562180-24-002880
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-03-20 16:32:31
Reporting Period:
2024-03-18
Accepted Time:
2024-03-20 16:32:31
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1560241 G1 Therapeutics Inc. GTHX Pharmaceutical Preparations (2834) 263648180
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1967910 V W. John Umstead 700 Park Offices Drive, Suite 200
Research Triangle Park NC 27709
Chief Financial Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2024-03-18 6,547 $3.02 123,896 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Footnotes
  1. The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a "sell-to-cover" transaction and do not represent discretionary transactions by the Reporting Person.
  2. The price represents the weighted average price with a low of $2.95 and a high of $3.16. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. Represents (i) 9,421 shares of common stock; (ii) 425 RSUs from award granted on January 4, 2021; (iii) 2,000 RSUs from award granted on January 3, 2022; (iv) 2,250 RSUs from award granted on January 3, 2023; (v) 37,500 RSUs from award granted on March 15, 2023; (vi) 35,000 RSUs from award granted on May 10, 2023; and (vii) 37,300 RSU's granted on January 3, 2024.